Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen Inc. (BIIB) Stock Moves -0.36%: What You Should Know
10:00pm, Wednesday, 31'st Aug 2022 Zacks Investment Research
Biogen Inc. (BIIB) closed the most recent trading day at $195.38, moving -0.36% from the previous trading session.
Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know
10:00pm, Thursday, 25'th Aug 2022 Zacks Investment Research
Biogen Inc. (BIIB) closed the most recent trading day at $204.83, moving +1.51% from the previous trading session.
Lecanemab And Biogen's Path To Growth
03:05am, Monday, 22'nd Aug 2022
There is a critical upcoming catalyst for Biogen shareholders, a topline read out of data from the CLARITY-AD trial in Alzheimer's due in late September. One lesson from the Aduhelm fiasco is that dat
Biogen Inc. (BIIB) Up 1.1% Since Last Earnings Report: Can It Continue?
03:30pm, Friday, 19'th Aug 2022 Zacks Investment Research
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Axsome Therapeutics Stock Is Crushing It Today
03:20pm, Friday, 19'th Aug 2022 The Motley Fool
The biotech's drug for major depressive disorder has been formally approved by the FDA.
Here's What Could Make This Beaten-Down Stock a Buy
02:30pm, Friday, 19'th Aug 2022 The Motley Fool
The future looks a bit murky for this biotech giant.
Biogen Inc. (BIIB) Up 1.1% Since Last Earnings Report: Can It Continue?
12:48pm, Friday, 19'th Aug 2022
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock?
How Are Biotech ETFs Reacting to Q2 Earnings Releases?
12:00pm, Thursday, 18'th Aug 2022 Zacks Investment Research
he Biotech sector has been in a sweet spot for quite some time now. Plus, earnings releases have also come in mostly upbeat.
How Are Biotech ETFs Reacting to Q2 Earnings Releases?
09:02am, Thursday, 18'th Aug 2022
he Biotech sector has been in a sweet spot for quite some time now. Plus, earnings releases have also come in mostly upbeat.
Eli Lilly's (LLY) Potential New Products Key to Growth
02:15pm, Monday, 15'th Aug 2022 Zacks Investment Research
Lilly (LLY) expects to launch five new medicines by 2023 end including Mounjaro for type II diabetes (already launched) and donanemab for early Alzheimer's disease.
7 F-Rated Stocks to Avoid Now
02:30pm, Friday, 12'th Aug 2022
The best investors know how to identify winners and fill their portfolios with equities that have the best potential for returns. And at the same time, they know which stocks to avoid.
Covid Exposed A 'Brain Health Pandemic' — Here's How Biotech Stocks Like Biogen, Sage Therapeutics Could Help
10:50am, Thursday, 11'th Aug 2022
The "brain health pandemic" since Covid struck exposed a glaring void: Current depression treatments don't fit many patients' needs. A group of biotech stocks hope to change that.
Ionis (IONS) Q2 Earnings & Sales Miss Estimates, Stock Down
12:14pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.
Denali (DNLI) Q2 Earnings Beat, Pipeline Progress in Focus
02:53pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Denali (DNLI) incurs narrower-than-expected Q2 loss while collaboration revenues beat estimates.
Teva Pharmaceutical: A Gem Among Generic Pharmaceutical Companies
05:25am, Sunday, 07'th Aug 2022 Seeking Alpha
Teva Pharmaceutical's revenue was $3,786 million in Q2 2022, up 3.4% QoQ. See why we believe there is huge potential for TEVA stock with target price of $25.
